MCF7/AnaR-3 Cell Line

The MCF7/AnaR-3 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI anastrozole allows the study of the molecular basis for resistance to AIs to…

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society
SKU: 152553
Product description: The MCF7/AnaR-3 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI anastrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment. Human breast cancer cell line derived from MCF7 cells
Conditional: No
Production details: Anastrozole-resistant cell lines were established from MCF7 cells grown in medium with 10% NCS and 10â?‚ˆ?‚Â’7 M testosterone. A culture of MCF7 cells were treated with 10â?‚ˆ?‚Â’7 M anastrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with anastrozole. After ~2â?‚€?‚“3 months, the isolated colonies gave rise to anastrozole-resistant cell lines, which could be grown i…
Cellosaurus ID: CVCL_5A11
Parental cell line: MCF7
Disease: Cancer
Cat. #: 152553
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer;Drug development
Organism: Human
Tissue: Breast
Growth properties: Breast cancer cell line resistant to the aromatase inhibitor anastrozole. Estrogen receptor positive.
Cancer Types In Detail: Breast cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM anastrozole.
References:

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Images

View Gallery
MCF7 AnaR-3 Cell Line. Early log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Related Tools for Cell lines

Cat. # Tool Name
151445 1-7HB2 Cell Line Key Info View Tool
151503 1-7 CE1 Cell Line Key Info View Tool
151014 MCF7 AREc32 Cell Line Key Info View Tool
151558 MEF Trex1 KO Cell Line Key Info View Tool
151559 MEF UNG KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.